Review of precocious puberty part II: Gonadotropin-independent precocious puberty

Endocrinologist

Volumn 10, Issue 6, 2000, Pages 397-402

  Tang, M ^a   Fenton, C ^a   Poth, M ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIFUNGAL AGENT; AROMATASE INHIBITOR; BUSERELIN; CYPROTERONE ACETATE; DESLORELIN; GONADORELIN; GONADOTROPIN; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; SEX HORMONE; SPIRONOLACTONE; TESTOLACTONE;

ADRENAL TUMOR; ALBRIGHT SYNDROME; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; GONAD TUMOR; GONADOTROPIN RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; PATHOGENESIS; PATHOPHYSIOLOGY; PRECOCIOUS PUBERTY; REVIEW;

EID: 0034533275     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200010060-00006     Document Type: Review

References (24)

1. New aspects in the diagnosis and treatment of pubertal disorders
2. Premature thelarche and precocious puberty
3. The biological aspects of puberty
4. Evaluation and management of precocious puberty
5. Precocious puberty
6. Pathophysiology and treatment of sexual precocity
7. Advances in the treatment of precocious puberty
8. Disorders of puberty: Inactivating and activating molecular mutations
9. Gonadotropin-independent precocious puberty
10. Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report
11. McCune-Albright syndrome: How many endocrinopathies can one patient have?
12. McCune-Albright syndrome. Long-term follow-up
13. s
14. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone
15. Longterm testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome
16. Testotoxicosis: An unusual presentation and novel gene mutation
17. Identification of constitutively activating mutation of the LH receptor in a family with male limited gonadotrophinindependent precocious puberty (testotoxicosis)
18. Male-limited familial precocious puberty in three generations: Apparent Leydig-cell automony and elevated glycoprotein hormone alpha subunit
19. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): Effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases
20. Gonadotopin independent precocious puberty
21. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy
22. Hazards of ketoconazole therapy in testotoxicosis
23. Treatment of familial male precocious puberty with spironolactone and testolactone
24. Treatment of familial male precocious puberty with spironolactone, testolactone and deslorelin